Version history

{
  "session_id": "sess_SDA-2026-04-15-gap-pubmed-20260411-083043-759b4c5e_20260416-033650",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Response: Translational Evaluation of ApoE-Dependent CAA Hypotheses\n\n## Preamble: Positioning Within Current Therapeutic Landscape\n\nThe source paper's foundational observation—that apoE is *absolutely required* for CAA development—remains clinically unexploited. Current FDA-approved anti-amyloid antibodies (lecanemab, donanemab, aducanumab) target parenchymal plaque but have shown limited efficacy against CAA, and carry substantial ARIA-H (hemorrhage) risk that may relate to vascular amyloid mobilization. This creates a distinct clinical opportunity: therapeutic strategies targeting the apoE-Aβ vascular deposition axis could complement existing approaches or address patient subsets excluded from current regimens.\n\n---\n\n## 1. High-Translational-Potential Hypotheses\n\n### Hypothesis A: ApoE Lipidation State as Determinant of Aβ Vascular Seeding vs. Clearance\n\n**Translational Ranking: HIGHEST**\n\nThis hypothesis posits that apoE's lipidation status—governed by ABCA1/ABCG1-driven cholesterol efflux and HDL remodeling—determines whether apoE functions as an Aβ \"seed\" (poorly lipidated) or a clearance vehicle (highly lipidated). This is mechanistically distinct from the Theorist's structural proposal because it is directly pharmacologically tractable.\n\n**Clinical Evidence Base:**\n\n| Modality | Evidence | Source |\n|----------|----------|--------|\n| Genetic | ABCA1 loss-of-function mutations cause reduced HDL and altered Aβ metabolism in humans | Wollmer et al., 2003, PMID: 12886326 |\n| Epidemiological | ABCA1 polymorphisms associated with AD risk modification by apoE4 status |ji et al., 2008, PMID: 18316727 |\n| Preclinical | ABCA1 haploinsufficiency in APP/PS1 mice increases parenchymal and vascular Aβ | Hirsch-Reinshagen et al., 2009, PMID: 19293257 |\n| Post-mortem | Poorly lipidated apoE in AD/CAA brain tissue vs. well-lipidated in healthy aged | Wildsmith et al., 2014, PMID: 24448007 |\n\n**Patient Population Fit:**\n- **Primary:** Diagnosed CAA (Boston criteria",
  "tokens_used": "501"
}